June 25, 2019
Shionogi is out-licensing its thrombopoietin receptor agonist Mulpleta (lusutrombopag) and HER2/EGFR inhibitor epertinib to China’s Eddingpharm Group, the Osaka drug maker said on June 24. Under the deal, Eddingpharm has been granted exclusive commercialization rights for Mulpleta in mainland China,...read more